Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Functional EGFP-dystrophin fusion proteins for gene therapy vector development.

P Chapdelaine1, P A Moisset, P Campeau

  • 1Unité de Recherche en Génétique Humaine, Centre Hospitalier de l'Université Laval, CHUQ, Faculté de Médecine, Université Laval, Sainte-Foy, Québec, G1V 4G2, Canada.

Protein Engineering
|October 31, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and factors associated with active cybersexuality among teenagers between 15 and 17 years old: a cross sectional study in Normandy, France.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2023
Same author

Intramuscular Migration of Myoblasts Transplanted after Muscle Pretreatment with Metalloproteinases.

Cell transplantation·2017
Same author

Chondrodysplasia with multiple dislocations: comprehensive study of a series of 30 cases.

Clinical genetics·2017
Same author

Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia.

Gene therapy·2016
Same author

Development of an AAV9 coding for a 3XFLAG-TALEfrat#8-VP64 able to increase in vivo the human frataxin in YG8R mice.

Gene therapy·2016
Same author

[Emergency contraceptions: Propositions of the Orthogenics Commission of the French National College of Gynecology and Obstetrics].

Gynecologie, obstetrique & fertilite·2015
Same journal

Structure of a human Rhinovirus complexed with its receptor molecule.

Protein engineering·2024
Same journal

pH-responsive polymer-assisted refolding of urea- and organic solvent-denatured alpha-chymotrypsin.

Protein engineering·2004
Same journal

Evaluation of different linker regions for multimerization and coupling chemistry for immobilization of a proteinaceous affinity ligand.

Protein engineering·2004
Same journal

Recombinant porcine intestinal carboxylesterase: cloning from the pig liver esterase gene by site-directed mutagenesis, functional expression and characterization.

Protein engineering·2004
Same journal

Periplasmic expression of human growth hormone via plasmid vectors containing the lambdaPL promoter: use of HPLC for product quantification.

Protein engineering·2004
Same journal

Shift of fibril-forming ability of the designed alpha-helical coiled-coil peptides into the physiological pH region.

Protein engineering·2004
See all related articles

Researchers fused enhanced green fluorescent protein (EGFP) to dystrophin mini-genes to improve gene therapy for Duchenne muscular dystrophy. This fusion allows for easier detection of transgene-expressing cells, aiding in developing effective delivery methods.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Biochemistry

Background:

  • Gene therapy for Duchenne muscular dystrophy is challenged by the large size of dystrophin cDNAs, leading to low expression yields.
  • Current methods for detecting dystrophin-expressing cells are inefficient and costly.

Purpose of the Study:

  • To develop an improved method for delivering dystrophin cDNA for Duchenne muscular dystrophy gene therapy.
  • To create expression vectors fusing enhanced green fluorescent protein (EGFP) with dystrophin mini- and full-length cDNAs.
  • To assess the efficacy and localization of these EGFP-dystrophin fusion proteins in vitro and in vivo.

Main Methods:

  • Construction of expression vectors encoding EGFP-dystrophin fusion proteins (mini- and full-length).
  • Transfection of Phoenix cells with Effectene reagent to test in vitro expression.

Related Experiment Videos

  • Immunoblotting analysis using a dystrophin C-terminus specific antibody to confirm protein expression and size.
  • In vivo electroporation of plasmids into mouse muscles, followed by cryosectioning and fluorescence microscopy.

    • Main Results:

    • Transfection yielded a green fluorescent signal in 20% of cells, indicating successful expression of EGFP-dystrophin fusion proteins.
    • Immunoblotting confirmed the expression of 240 kDa (EGFP-mini-dystrophin) and 450 kDa (EGFP-full-length dystrophin) fusion proteins.
    • In vivo electroporation resulted in correct plasma membrane localization of EGFP-dystrophin in mouse muscle fibers.

    Conclusions:

    • Fusion of EGFP to dystrophin or mini-dystrophin does not impede normal protein localization.
    • EGFP fusion serves as an effective tool for optimizing the delivery of dystrophin cDNA in vitro and in vivo.
    • This approach facilitates the development of gene therapy strategies for Duchenne muscular dystrophy.